M Chumbita
Overview
Explore the profile of M Chumbita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Pouton N, Peyrony O, Chumbita M, Aiello F, Monzo P, Gallardo-Pizarro A, et al.
Rev Esp Quimioter
. 2023 Nov;
36 Suppl 1:52-53.
PMID: 37997872
Chimeric antigen receptor (CAR) T cell therapy targeting CD-19 has revolutionized the treatment of refractory B-cell malignancies. However, patients undergoing this therapy face an increased risk of infections due to...
2.
Tellez Santoyo A, Lopera C, Ladino Vasquez A, Segui Fernandez F, Grafia Perez I, Chumbita M, et al.
Rev Esp Quimioter
. 2023 Aug;
36(6):592-596.
PMID: 37575020
Objective: Clinical data on which artificial intelligence (AI) algorithms are trained and tested provide the basis to improve diagnosis or treatment of infectious diseases (ID). We aimed to identify important...
3.
Chumbita M, Monzo-Gallo P, Lopera-Marmol C, Aiello T, Puerta-Alcalde P, Garcia-Vidal C
Rev Esp Quimioter
. 2022 Oct;
35 Suppl 3:51-53.
PMID: 36285859
Ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol belong to a novel generation of antibiotics that correspond with the β-lactam family. It is necessary to having new options in treating infections caused by Gram-negative,...
4.
Chumbita M, Puerta-Alcalde P, Garcia-Pouton N, Garcia-Vidal C
Rev Esp Quimioter
. 2021 Oct;
34 Suppl 1:72-75.
PMID: 34598433
Invasive fungal infection often complicates patients with severe viral infection, especially those admitted to critical care units. Severe SARS-CoV-2 infection has been no exception and a significant association with Aspergillus...
5.
Meira F, Albiach L, Carbonell C, Martin-Oterino J, Martin-Ordiales M, Linares L, et al.
Rev Esp Quimioter
. 2021 May;
34(4):337-341.
PMID: 33982984
Objective: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of...
6.
Moreno-Garcia E, Rico E, Albiach L, Aguero D, Ambrosioni J, Bodro M, et al.
Rev Esp Quimioter
. 2021 Apr;
34(3):238-244.
PMID: 33829722
Objective: In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation...
7.
Garcia-Vidal C, Meira F, Cozar-Llisto A, Duenas G, Puerta-Alcalde P, Garcia-Pouton N, et al.
Rev Esp Quimioter
. 2021 Mar;
34(2):136-140.
PMID: 33675220
Objective: Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain. Methods: We performed a...
8.
Moreno-Garcia E, Chumbita M, Puerta-Alcalde P, Cardozo C, Garcia-Vidal C
Rev Esp Quimioter
. 2019 Sep;
32 Suppl 2:59-62.
PMID: 31475813
Invasive fungal infection continues to be an important cause of morbidity and mortality in haematological patients. Antifungal prophylaxis in these patients has remarkably increased survival since its introduction. In recent...
9.
Viasus D, Puerta-Alcalde P, Cardozo C, Suarez-Lledo M, Rodriguez-Nunez O, Morata L, et al.
Clin Microbiol Infect
. 2019 Jul;
26(3):345-350.
PMID: 31295551
Objectives: To assess risk factors for multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infection in neutropenic patients. Methods: Single-centre retrospective analysis of consecutive bloodstream infection (BSI) episodes (2004-2017, Barcelona). Two multivariate regression models...